The European Microbiome Innovation for Health (EMIH) Association has significantly expanded its coalition, welcoming 13 new members. This strategic growth highlights Europe’s robust leadership in microbiome innovation and underscores EMIH’s commitment to enhancing medical solutions through microbiota-based therapies.

The newly integrated members represent a diverse array of leading entities, ranging from private biotechnology and pharmaceutical companies to patient advocacy groups and consulting firms. Among the notable newcomers are BioGaia, a Swedish healthcare company renowned for its probiotics sold globally, and Cancer Patients Europe, an influential pan-European patient association advocating for reduced cancer burdens through research and policy.

Innovative biotechnology companies, including EnteroBiotix, Microviable, and Microbiotica, join EMIH, each bringing unique expertise in therapeutic microbiome interventions for gastrointestinal diseases, infectious diseases, oncology, and inflammatory conditions. Notably, Institut Mérieux, an international leader in biological medicine and diagnostics, also joins, further amplifying EMIH’s global reach and technological prowess.

Additional members include the International Probiotics Association – Europe (IPA Europe), championing regulatory clarity and safety standards for probiotics, and consulting and legal experts Life Avocats and Nextep, specialized in regulatory and systemic healthcare transformations. Furthermore, Mbiomics and SwipeBiome bring advanced precision analytics and AI-driven personalized microbiome solutions to the association.

The expansion aligns with EMIH’s goal of fostering Europe’s microbiome sector through collaborative innovation, rigorous regulatory frameworks, and equitable patient access. As emphasized by Hervé Affagard, EMIH’s president, this growth underscores Europe’s increasing influence in microbiome advancements, positioning the continent as a global frontrunner in microbiome-based medical innovation.

Through this reinforced collaboration, EMIH and its members aspire to deliver impactful therapeutic innovations, significantly enhancing patient outcomes and healthcare practices across Europe and beyond.